Viemed Healthcare, Inc.
NASDAQ:VMDMedical - Devices
+$0.07 today
- Market cap
- $326.26M
- Beta
- 1.13
- P/E (TTM)
- 27.4
- EPS (TTM)
- $0.39
Volume 0.17M
Average 0.26M
Financial health
Viemed Healthcare, Inc. financial health
Start with the overall verdict and the rule-based risk checks for VMD, then work through liquidity, debt, balance-sheet quality, and claims on cash.
Financial health snapshot
Debt service and balance sheet cushion look healthy, even if some working-capital ratios deserve context.
Cash & Investments
$12.56M
Debt Cushion
$119,000.00
Current Ratio
1.2x
Interest Coverage
15.5x
Risk checks
1 of 11 checks flagged
Debt growth versus revenue growth
184.3% vs. 24.9%
Passes when: Over three years, debt growth is no more than 5 percentage points above revenue growth.
Positive equity
Positive
Passes when: Shareholders’ equity is above zero.
Interest coverage
18.4×
Passes when: Operating income is at least 1.5 times interest expense.
Short-term liquidity
1.2×
Passes when: Current assets are at least 1 times current liabilities.
Near-term debt coverage
11.2×
Passes when: Cash and short-term investments cover debt due within 12 months.
Manageable net debt
0.1×
Passes when: Net debt is below 3 times EBITDA.
Debt repayment from cash flow
0.5 yr
Passes when: Free cash flow could repay all debt within 5 years.
Tangible equity base
41.8%
Passes when: Goodwill and intangibles are below 50% of equity.
Altman Z-score trend
6.68 → 4.71
Passes when: The Z-score is stable or rising, or stays above 2.99.
Stock-based compensation
16.2%
Passes when: Stock-based compensation is no more than 20% of operating cash flow.
Share dilution
+0.1% per year
Passes when: Diluted share count grows no more than 2% per year.
Financial strength scores
How strong are the fundamentals over time?
Piotroski tests profitability, balance-sheet direction, and efficiency; Altman estimates bankruptcy risk. Compare the current scores with their fiscal-year history.
Financial strength scores
Piotroski F-Score and Altman Z-Score from the latest reported financials
Piotroski F-Score
Strong8 / 9
Nine pass/fail tests of profitability, balance-sheet strength, and efficiency. 8–9 is strong, 0–3 is weak.
Altman Z-Score
Safe zone6.42
Bankruptcy-risk model. Above 2.99 is the safe zone, 1.81–2.99 the grey zone, and below 1.81 the distress zone.
Score history
Piotroski F-Score and Altman Z-Score recalculated from each fiscal year's statements and year-end market value.
| Score | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Piotroski F (0–9) | 4 | 7 | 6 | 3 | 7 | 6 | 6 | 5 | 6 | 4 |
| Altman Z | 5.60 | 5.85 | 7.85 | 5.54 | 8.87 | 7.83 | 11.26 | 6.66 | 6.68 | 4.71 |
Piotroski: 8–9 strong, 4–7 average, 0–3 weak. Altman: above 2.99 safe, 1.81–2.99 grey, below 1.81 distress. Our calculation can differ slightly from the provider's current scores above.
Liquidity
Can it meet short-term obligations?
Check whether cash and current assets cover what falls due within a year without depending on fresh financing.
Cash & Equivalents
$9.76M
Q1 2026
Quick Ratio
1.1x
Q1 2026
Current Ratio
1.2x
Q1 2026
Cash Ratio
0.2x
Q1 2026
Working capital
How quickly does cash come back?
Receivable, inventory, and payable days show how much cash the operating cycle ties up and whether that is changing.
Working capital and cash conversion
Annual days measures from year-end receivables, inventory, and payables against revenue and cost of revenue.
Working capital (Q1 2026)
$9.11M
Current assets − current liabilities
Days sales outstanding
35 d
-6 days vs. prior year
Days inventory outstanding
16 d
-1 days vs. prior year
Days payables outstanding
39 d
+2 days vs. prior year
Cash conversion cycle
11 d
-9 days vs. prior year
Leverage
How much debt risk sits on the balance sheet?
Review total borrowings, debt relative to equity and assets, and whether operating profit covers interest costs.
Total Debt
$12.44M
Q1 2026
Debt/Equity
0.1x
Q1 2026
Debt/Assets
0.1x
Q1 2026
Interest Coverage
15.5x
Q1 2026
Debt service
Can cash flow carry the debt?
Measure debt against EBITDA and free cash flow, see how much is due within 12 months, and follow debt and cash over time.
Debt service capacity
Can operating cash flow carry the debt, and how much is due soon?
Net debt
$2.68M
Total debt − cash − short-term investments
Net debt / EBITDA
0.1×
Above 3× is elevated
Free cash flow / debt
208.4%
Share of debt one year of FCF could repay
Years to repay debt
0.5 yr
Total debt ÷ free cash flow
Operating cash flow / current liabilities
1.4×
Above 1× funds a year of obligations
Interest coverage
18.4×
Operating income ÷ interest expense
Debt maturity
Cash and short-term investments cover short-term debt 11.2×.
Balance sheet as of Q1 2026; cash flows TTM to Q1 2026.
Debt and cash over time
Fiscal-year-end borrowings against liquid assets; net debt below zero means net cash.
Balance sheet cushion
How much room is there if conditions weaken?
Extra cash and investments, and the balance of assets against liabilities, give the company room when trading gets harder.
Long-Term Investments
$2.79M
Q1 2026
Assets
$197.36M
Q1 2026
Liabilities
$51.56M
Q1 2026
Balance sheet quality
Who funds the assets, and how tangible is the equity?
Split the claims on assets between suppliers, lenders, customers, and shareholders, and see how much equity rests on goodwill and intangibles.
Balance sheet quality
Who funds the assets, and how much of the equity is tangible (Q1 2026).
Claims on $197.36M in assets
- Payables6.8%
- Short-term debt0.4%
- Long-term debt4.2%
- Deferred revenue3.8%
- Other liabilities10.9%
- Equity73.9%
Goodwill + intangibles
$60.16M
30.5% of total assets
Share of equity
41.8%
Above 50% leaves little tangible backing
Tangible equity
$83.7M
Equity left after writing off goodwill and intangibles
Deferred revenue
$7.48M
Customer prepayments: a liability settled by delivering service, not cash
Competitor health
How does Viemed Healthcare, Inc. compare with peers?
Compare leverage, interest coverage, and liquidity ratios with similar companies.
Competitor Health
Peer financial health comparison
| Company | Market Cap | D/E | D/Assets | ND/EBITDA | Int. Cov. | Quick | Current | Cash |
|---|---|---|---|---|---|---|---|---|
Sight Sciences, Inc. SGHT:NASDAQ | $601.92M | 0.64 | 0.35 | 1.56 | — | 9.52 | 10.22 | 8.34 |
Senseonics Holdings, Inc. SENS:NASDAQ | $579.58M | 0.68 | 0.33 | Net cash | — | 4.55 | 4.83 | 1.67 |
908 Devices Inc. MASS:NASDAQ | $405.01M | 0.12 | 0.09 | 3.33 | — | 3.86 | 4.24 | 3.32 |
Electromed, Inc. ELMD:AMEX | $198.79M | 0.00 | 0.00 | Net cash | — | 3.99 | 4.31 | 1.46 |
Inogen, Inc. INGN:NASDAQ | $147.95M | 0.09 | 0.06 | 31.71 | — | 2.71 | 3.12 | 1.63 |
Quanterix Corporation QTRX:NASDAQ | $139.11M | 0.13 | 0.09 | Net cash | — | 2.11 | 2.84 | 0.40 |
Outset Medical, Inc. OM:NASDAQ | $70.32M | 0.80 | 0.38 | Net cash | — | 5.40 | 6.67 | 0.93 |
Nano-X Imaging Ltd. NNOX:NASDAQ | $25.36M | 0.06 | 0.05 | 0.84 | — | 3.77 | 3.96 | 2.91 |
CVRx, Inc. CVRX:NASDAQ | $17.30M | 1.29 | 0.48 | 0.53 | — | 6.72 | 7.63 | 5.69 |
SANUWAVE Health Inc. SNWV:NASDAQ | $15.66M | 14.19 | 0.62 | 0.57 | 0.79 | 1.05 | 1.38 | 0.67 |
Questions
Financial health questions
Common questions about VMD's balance sheet, answered from the reported figures.
Is VMD's balance sheet healthy?
Viemed Healthcare, Inc. (VMD) has a current ratio of 1.22, a quick read on short-term liquidity.
How leveraged is VMD?
Debt to equity is 0.09, which helps judge how much financing risk sits on the balance sheet.
Continue the stock analysis
Jump to another research area for this company.